Events

Cannabis Health Symposium London: Complete Session Guide — Who’s Speaking and Why it Matters

Everything you need to know about the Cannabis Health Symposium in London next week.

The Cannabis Health Symposium returns to Conway Hall, London, on Thursday 26 November, bringing together healthcare professionals, researchers, industry leaders and patient advocates to bridge the gap between the emerging evidence base and the realities of prescribing cannabis-based medicines.

Following the success of Cannabis Health‘s London Symposium last year, and Frankfurt earlier this month, the event is designed to provide the knowledge, tools, and peer exchange that healthcare professionals need to practise confidently in an evolving landscape.

Taking place eight years after the legalisation of medical cannabis in the UK, the CPD-certified symposium will explore the challenges shaping the sector, from research and regulation to clinical practice, patient safety and access.

The programme features 21 sessions, including four panel debates, with leading experts in cannabinoid science, psychiatry, pain management and healthcare policy.

Here are some of the key sessions and confirmed speakers to look out for.

Policy, regulation and patient rights

Opening the morning programme at 10 am, Professor Trevor Jones, co-chair of the UK Cannabinoid Research and Development Group, will join Cannabis Health’s Sarah Sinclair to discuss what is needed to establish the UK as a global leader in cannabinoid science.

The fireside conversation will explore barriers to research, including Schedule 1 licensing restrictions, and the regulatory changes needed to support clinical trials and the development of licensed medicines.

At 10:20 am, Dr David Tang, CEO and founder of CannPrescribe, will contribute to a panel on building safe, effective and compliant medical cannabis services, examining clinical governance, Care Quality Commission (CQC) expectations and patient safety.

Professor Kim Wolff, Director of King’s Forensics at King’s College London, will then address the challenges surrounding medical cannabis in the workplace at 11 am, including drug testing, employee rights and safety-critical roles.

The morning will also feature a session on police guidance for medical cannabis patients, with Former Detective Chief Superintendent and Controlled Drug Liaison Officer, Richard List QMP, exploring the practical implications of the law and the responsibilities of patients, clinicians and law enforcement.

Clinical evidence and prescribing in practice

The afternoon programme will focus on the evidence underpinning cannabis-based medicines and the implications for clinical practice.

At 2 pm, Edward Chesney, Clinical Lecturer at King’s College London, and Dr Iain Pryde, Consultant Psychiatrist at Tilray Medical x Lyphe Clinic, will examine the potential benefits and risks of medical cannabis in mental health care, in a session moderated by Kate Thorpe, executive director of the Medical Cannabis Clinicians Society.

The discussion will address concerns around dependency, psychosis risk, patient selection and how clinicians can make informed prescribing decisions.

At 3 pm, Professor David Nutt, Professor of Neuropsychopharmacology at Imperial College London and founder of Drug Science, will explore one of the most pressing questions in cannabinoid research: whether it is time to look beyond randomised controlled trials (RCTs). His session will consider the role of real-world evidence (RWE) in evaluating the safety and effectiveness of cannabis-based medicines, particularly where conventional clinical trial data remains limited.

Professor Mike Barnes, consultant neurologist and chair of the MCCS, will then explore the growing interest in the use of cannabis-based medicines for neurodevelopmental and neurological conditions, with a presentation at 2.40 pm.

Women’s health will also be in focus, with Dr Grace Blest-Hopley, founder of Hystelica, examining the emerging evidence for medical cannabis in conditions including endometriosis, menopause, premenstrual dysphoric disorder (PMDD) and chronic pelvic pain at 3:30 pm.

At 3:50 pm, Dr Simon Tordoff, Consultant in Pain Management at CB1 Medical, and Garvin Hirt, co-founder and CEO of Copeia, will discuss what real-world evidence can tell us about medical cannabis in chronic pain management.

Drawing on registry data and clinical experience, the panel will explore treatment outcomes, potential opioid-sparing effects and the evidence gaps that remain.

The main programme will conclude with a patient round-table at 4:20 pm, featuring Liam O’Dowd, editor and co-founder of leafie, highlighting the importance of lived experience in improving clinical care.

Interactive workshops and practical insights

Alongside the main programme, a dedicated workshop stage will offer opportunities for more focused discussions.

Highlights include a patient discrimination workshop with Alex Fraser, founder of Patient Protect, examining the barriers patients face in employment, policing and healthcare.

Shanna Marrinan, Director of Research at 4C Labs, will present findings from an analysis of UK drug-checking data, exploring the implications of illicit market contamination for patient safety.

Meanwhile, Dr Anna Waldstein, Senior Lecturer in Medical Anthropology at the University of Kent, will examine how social and cultural factors influence outcomes in medical cannabis treatment.

The workshop programme will also explore international prescribing frameworks, nursing and the economics of patient self-sufficiency.

Cannabis Health Symposium London 2026: tickets and essential information

The Cannabis Health Symposium takes place on Thursday 26 November 2026, from 8:30 am to 5 pm, at Conway Hall, 25 Red Lion Square, London WC1R 4RL.

The event is certified by The CPD Certification Service and is open to healthcare professionals, researchers, industry representatives, and patient advocates.

Final Release tickets are priced at £284.09, with concession tickets available for healthcare professionals at £100, subject to verification.

All tickets include 12 months’ free membership of the Medical Cannabis Clinicians Society (MCCS), worth up to £120.

With just one week to go, healthcare professionals and other interested attendees are encouraged to secure their place.

View the full programme and book your ticket for the Cannabis Health Symposium London 2026 here.

News Editor

News Editor

Evidence-led reporting on cannabis science, medicine and policy across the UK and Europe.